The fact that the transcriptional activation of downstream oncogenes can result from the loss of repressive H3K27me3 mark, led us to hypothesize that the ectopic expression of histone demethylase such as KDM6B may be a reasonable therapeutic target in AML. This evidence concerns the gene KDM6B and acute myeloid leukemia.